Latest quarter
Gilead reported Q3 FY2026 revenue of $8.3 billion, above the $7.8 billion consensus, and adjusted earnings of $2.55 per share, above the $2.17 consensus. Revenue rose from $7.8 billion a year earlier, while diluted earnings per share fell to $1.94 from $2.43.
The filing attributed revenue growth primarily to HIV products, Trodelvy and Livdelzi, partly offset by lower Veklury and cell therapy sales and lower royalty and other revenue. HIV product sales rose 18% to $6.2 billion, helped by pricing, prevention demand and inventory; Trodelvy sales increased 42% to $506 million on higher demand. Cell therapy sales declined 18% to $355 million, which the filing attributed to lower demand amid competition.
Gilead’s filing attributed the decline in net income primarily to equity-security losses, compared with gains a year earlier, and higher income tax expense. Gross margin rose to 81.1% from 79.8%, while operating margin declined to 41.7% from 42.8%. Free cash flow increased to $4.8 billion from $4.0 billion.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $8.3 billion | $7.8 billion | 6.83% |
| Diluted EPS | $1.94 | $2.43 | −20.1% |
| Gross margin | 81.1% | 79.8% | 1.3 percentage points |
| Operating margin | 41.7% | 42.8% | −1.1 percentage points |
| Free cash flow | $4.8 billion | $4.0 billion | 21.1% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $2.55 | $2.17 | Beat by 17.5% |
| Revenue | $8.3 billion | $7.8 billion | Beat by 6.21% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
Chief commercial officer Johanna Mercier said HIV sales benefited from demand, favorable pricing and a larger-than-usual third-quarter inventory build across the portfolio. In response to a question about the quarter, she said differences in discounts across sales channels could cause pricing to fluctuate. Mercier added that the usual fourth-quarter inventory build could consequently be smaller than normal, although she still expected a buildup.
CEO Daniel O’Day said prevention sales nearly doubled year over year and that Yeztugo and Descovy for PrEP had a combined $4 billion annual run rate. He said Trodelvy reached an approximately $2 billion annual run rate as demand grew across metastatic breast cancer types.
CFO Andrew Dickinson said third-quarter non-GAAP product gross margin rose to 88% from 86% a year earlier, primarily because a royalty obligation expired. He said non-GAAP selling, general and administrative expenses increased as Gilead supported HIV promotion and incurred legal expenses and higher compensation accruals. Asked about margins and spending, Dickinson said the company had absorbed much of the expense from acquisitions completed earlier in the year and intended to continue managing operating costs.
Asked about Medicare pricing for Biktarvy, Mercier said the estimated revenue impact was primarily in Medicare, with effects across other US channels. She described the analysis as preliminary and said Gilead would not provide a detailed split yet. O’Day said he opposed the pricing policy, arguing that it could discourage investment in medicines.
On pipeline questions, chief medical officer Dietmar Berger said the 3107 monthly oral HIV program was on clinical hold after metabolites showed unexpected effects, while backup molecules remained in development. Kite executive vice president Cindy Perettie said Gilead had paused parts of the Palisades trials to investigate severe neurological events in a small number of patients.
Guidance
Gilead raised its FY2026 base business sales outlook to $30.7 billion–$31.0 billion from $29.4 billion–$29.8 billion. CFO Andrew Dickinson said the company now expects total product sales of $31.0 billion–$31.3 billion and HIV sales growth of approximately 12.0% for the year.
Dickinson said Gilead now expects approximately $12.9 billion in non-GAAP acquired research and development expense, including anticipated fourth-quarter upfront payments. Gilead’s updated outlook calls for a non-GAAP diluted loss per share of −$1.20 to −$0.85. Dickinson also said the company expects FY2026 research and development expenses to rise by a mid- to high-single-digit percentage from 2025.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| Gross margin | FY2027 | Gilead expects very strong gross margins in FY2027. | — | — |
| Revenue, Product Sales | FY2028 | Gilead expects product sales to grow in FY2028 compared with FY2027. | — | — |
| Revenue, Hiv | FY2028 | Gilead expects total HIV revenue to grow in FY2028 compared with FY2027. | — | — |
| Revenue, Biktarvy | FY2028 | Gilead expects FY2028 Biktarvy revenue to decline from FY2027. | — | — |
| Tax rate, Non Gaap Excluding Acquired Iprd Transactions | FY2026 | 20.0% | — | New |
| Tax rate, non-GAAP | FY2026 | 165.0%–220.0% | — | New |
| Research and development, non-GAAP | FY2026 | Gilead expects FY2026 non-GAAP R&D expenses to increase by a mid- to high-single-digit percentage from FY2025. | — | — |
| Research and development, Non Gaap Acquired Iprd | FY2026 | $12.9 billion | — | New |
| Revenue, Veklury | FY2026 | $300.0 million | $600.0 million | Cut |
| Revenue, Product Sales | FY2026 | $31.0 billion–$31.3 billion | — | New |
| Revenue, Cell Therapy | FY2026 | Gilead expects FY2026 cell therapy sales to decline by a mid-teens percentage year over year. | — | — |
| Revenue, Yeztugo | Q4 FY2026 | Gilead expects modest sequential Yeztugo sales growth in Q4 FY2026. | — | — |
| Revenue, Yeztugo | FY2026 | $1.0 billion | — | New |
| Revenue growth, Hiv | FY2026 | 12.0% | — | New |
| Revenue, Base Business | FY2026 | $30.7 billion–$31.0 billion | $29.4 billion–$29.8 billion | Raised |
| Tax rate, GAAP | FY2026 | −55.0%–−50.0% | 140.0%–190.0% | Cut |
| Gross margin, non-GAAP | FY2026 | 87.0% | — | New |
| Gross margin, GAAP | FY2026 | 79.0% | — | New |
| EPS, non-GAAP | FY2026 | −$1.20–−$0.85 | $0.65–$1.05 | Cut |
| EPS, GAAP | FY2026 | −$4.40–−$4.05 | — | New |
| EPS, Non Gaap Excluding Transaction Costs | FY2026 | $8.45–$8.85 | — | New |
| Operating income | FY2026 | $2.4 billion–$2.9 billion | — | New |
| Revenue, Yes2go | FY2026 | $1.0 billion | — | New |
| Revenue, Total Product Sales | FY2026 | $30.0 billion–$30.4 billion | — | New |